Canagliflozin ameliorates ulcerative colitis via regulation of TLR4/MAPK/NF-κB and Nrf2/PPAR-γ/SIRT1 signaling pathways
European Journal of Pharmacology · 2023-12 · 960 · 176166
DOI: 10.1016/j.ejphar.2023.176166 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Pharmacology, 2023-12. Verfasst von Hanan S Althagafy und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry, Faculty of Science, University of Jeddah, Jeddah, Saudi Arabia. Hauptthemen laut MEDLINE: Colitis, Ulcerative, NF-kappa B. Die Arbeit wurde bisher 45-mal zitiert (Crossref) und nennt 82 Literaturangaben. Gefördert von: Assiut University, Al-Azhar University, University of California.
Abstract (Originalsprache)
Ulcerative colitis (UC) is one of the most common subtypes of inflammatory bowel disease (IBD) that affects the colon and is characterized by severe intestinal inflammation. Canagliflozin is a widely used antihyperglycemic agent, a sodium-glucose cotransporter-2 (SGLT2) inhibitor that enhances urinary glucose excretion. This study aims to provide insights into the potential benefits of canagliflozin as a treatment for UC by addressing possible cellular signals. Acetic acid (AA; 4% v/v) was administered intrarectally to induce colitis. Canagliflozin is given orally at a dose of 10 mg/kg/day. Canagliflozin attenuates inflammation in AA-induced colitis, evidenced by significant and dose-dependently downregulation of p38 MAPK, NF-κB-p65, IKK, IRF3, and NADPH-oxidase as well as colonic levels of IL-6 and IL-1β and MPO enzymatic activity. Canagliflozin mitigates colonic oxidative stress by decreasing MDA content and restoring SOD enzymatic activities and GSH levels mediated by co-activating of Nrf2, PPARγ, and SIRT1 pathways. Moreover, an in-silico study confirmed that canagliflozin was specific to all target proteins in this study. Canagliflozin's binding affinity with its target proteins indicates and confirms its effectiveness in regulating these pathways. Also, network pharmacology analysis supported that canagliflozin potently attenuates UC via a multi-target and multi-pathway approach.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biochemistry, Faculty of Science, University of Jeddah, Jeddah, Saudi Arabia.
- Department of Pharmacology and Toxicology, Faculty of Pharmacy, Al-Azhar University, Assiut Branch, Assiut, 71524, Egypt. Electronic address: Faresali@azhar.edu.eg.
- Department of Pharmacology and Toxicology, Faculty of Pharmacy, Al-Azhar University, Assiut Branch, Assiut, 71524, Egypt.
- Department of Medical Laboratory Technology, Faculty of Applied Medical Sciences, University of Tabuk, Tabuk, 71491, Kingdom of Saudi Arabia.
- Biochemistry and Molecular Biology Department, Faculty of Pharmacy, Helwan University, Ain Helwan, Helwan, Cairo, Egypt.
- Department of Pharmacology and Toxicology, Faculty of Pharmacy, Egyptian Russian University, Cairo, Egypt.
Förderung
- Assiut University
- Al-Azhar University
- University of California
Zitieren
APA
Althagafy, H. S., Ali, F. E. M., Hassanein, E. H. M., Mohammedsaleh, Z. M., Kotb El-Sayed, M. I., Atwa, A. M., Sayed, A. M., & Soubh, A. A. (2023). Canagliflozin ameliorates ulcerative colitis via regulation of TLR4/MAPK/NF-κB and Nrf2/PPAR-γ/SIRT1 signaling pathways. European Journal of Pharmacology, 960, 176166. https://doi.org/10.1016/j.ejphar.2023.176166
Vancouver
Althagafy HS, Ali FEM, Hassanein EHM, Mohammedsaleh ZM, Kotb El-Sayed MI, Atwa AM, et al. Canagliflozin ameliorates ulcerative colitis via regulation of TLR4/MAPK/NF-κB and Nrf2/PPAR-γ/SIRT1 signaling pathways. European Journal of Pharmacology. 2023;960:176166. doi:10.1016/j.ejphar.2023.176166
BibTeX
@article{Althagafy2023,
author = {Althagafy, Hanan S and Ali, Fares E M and Hassanein, Emad H M and Mohammedsaleh, Zuhair M and Kotb El-Sayed, Mohamed I and Atwa, Ahmed M and Sayed, Ahmed M and Soubh, Ayman A},
title = {Canagliflozin ameliorates ulcerative colitis via regulation of TLR4/MAPK/NF-κB and Nrf2/PPAR-γ/SIRT1 signaling pathways},
journal = {European Journal of Pharmacology},
year = {2023},
volume = {960},
pages = {176166},
doi = {10.1016/j.ejphar.2023.176166}
}
EUVIMED